The present disclosure provided a blood cell analyzer, a control device and a blood analysis method thereof. In the method, a first reagent is mixed with a sample to obtain a first testing sample, and then a second reagent is mixed with the first testing sample for a further reaction to get a second testing sample for basophil classification and/or HGB measurement. A blood sample may be tested in one reaction cell through time-division multiplexing technology to obtain four groups leukocytes classification result and HGB result by single detection channel. Thus, the structure of the analyzer may be greatly simplified on the premise of guaranteeing the performance of the analyzer, the size and cost of the analyzer may reduce and a performance-price ratio of the analyzer may increase.

A sample analyzer prepares a measurement sample from a blood sample or a body fluid sample which differs from the blood sample; measures the prepared measurement sample; obtains characteristic information representing characteristics of the components in the measurement sample; sets either a blood measurement mode for measuring the blood sample, or a body fluid measurement mode for measuring the body fluid sample as an operating mode; and measures the measurement sample prepared from the blood sample by executing operations in the blood measurement mode when the blood measurement mode has been set, and measuring the measurement sample prepared from the body fluid sample by executing operations in the body fluid measurement mode that differs from the operations in the blood measurement mode when the body fluid measurement mode has been set, is disclosed. A computer program product is also disclosed.

Lateral flow immunoassay devices, systems and methods are provided for quantifying hemoglobin S in a sample. Point-of-care devices and methods for quickly and accurately monitoring a subject's level of hemoglobin S in a blood sample are provided.

A biosensor includes a base substrate; an electrode layer disposed on a main surface of the base substrate and including first and second electrode pairs, each pair including a working electrode and a counter electrode; a spacer substrate on the electrode layer and having first and openings, the first opening exposing a part of the first electrode pair and the second opening exposing a part of the second electrode pair; a first reagent layer containing a first reagent reactive with a sample and disposed in the first opening; a second reagent layer containing a second reagent reactive with the sample and disposed in the second opening; and a top cover substrate on the spacer substrate, the top cover substrate including an introduction portion having at least one introduction opening, the introduction portion overlapping a part of the first opening in the spacer substrate and a part of the second opening.

A component measurement device for measuring a component of interest in blood based on an optical property of a mixture containing a pigmentary component colored by a color reaction between the component of interest in the blood and a reagent, the component measurement device including: an absorbance obtaining unit configured to obtain a measured value of absorbance of the mixture at a measuring wavelength; and an absorbance correction unit configured to correct the measured value of absorbance of the mixture at the measuring wavelength based on information on scattered light and a ratio between reduced hemoglobin and oxygenated hemoglobin in erythrocytes.

A method includes estimating a value of a parameter indicative of an age or lifespan of a population of red blood cells of a subject, estimating a value of average glucose (AG) of the subject based on (i) the value of the parameter and (ii) a value indicative of an amount of glycated hemoglobin (HbA1c) of the subject, and providing information for treatment or diagnosis of a hyperglycemia condition of the subject based on the estimated value of AG.

A method and system for determining a concentration of one or more analytes in whole blood is provided. In one aspect of the invention, the system includes a channel configured to carry whole blood. The system further includes a light source configured to emit light on the channel. Additionally, the system includes an actuation module associable with the channel, wherein the actuation module is configured to generate a cell-free plasma layer in the channel. Furthermore, the system includes an optical module associable with the channel.

A sample analyzer prepares a measurement sample from a blood sample or a body fluid sample which differs from the blood sample; measures the prepared measurement sample; obtains characteristic information representing characteristics of the components in the measurement sample; sets either a blood measurement mode for measuring the blood sample, or a body fluid measurement mode for measuring the body fluid sample as an operating mode; and measures the measurement sample prepared from the blood sample by executing operations in the blood measurement mode when the blood measurement mode has been set, and measuring the measurement sample prepared from the body fluid sample by executing operations in the body fluid measurement mode that differs from the operations in the blood measurement mode when the body fluid measurement mode has been set, is disclosed. A computer program product is also disclosed.

The present invention relates to a method for predicting the concentration or the mass of hemoglobin or an approximation thereof, respectively, in a body fluid and/or an extracorporeal sample thereof of a patient at a later, second point of time, the patient having theoretically or in reality been administered a certain dose of an erythropoiesis stimulating agent at an earlier, first point of time. It relates further to a method for determining the dose of an erythropoiesis stimulating agent to be administered to a patient, to a method for determining whether a patient is affected by circumstances leading to the loss of hemoglobin, to corresponding devices and to an erythropoiesis stimulating medicament for use in the treatment of anemia.

The present disclosure relates to systems and methods for measuring glycated A1c hemoglobin. A glycated hemoglobin level measuring system includes a sample testing apparatus having a microchannel that compresses a blood sample traveling through, a first pair of electrodes coupled to the microchannel, and a second pair of electrodes coupled to the microchannel. The glycated hemoglobin level measuring system further includes an analysis apparatus having sensors coupled to the first and second pairs of electrodes and configured to calculate a travel time taken by a red blood cell to pass through the first and second pairs of electrodes. The glycated hemoglobin level measuring system can use the travel time to measure a rigidity of the red blood cells and the corresponding glycated hemoglobin level.